Certara has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 67% of filings. The United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where Certara is filings its patents..
Regeneron Pharmaceuticals and Immatics could be the strongest competitors for Certara
Patents related to genomics and cell & gene therapy lead Certara’s portfolio
Certara has the highest number of patents in genomics followed by, cell & gene therapy and rare diseases. For genomics, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead Certara portfolio followed by atrophy, and type 1 diabetes (juvenile diabetes)
Certara has highest number of patents in breast cancer followed by atrophy, type 1 diabetes (juvenile diabetes), acid sphingomyelinase deficiency (niemann-pick disease), and adrenoleukodystrophy (x-linked adrenoleukodystrophy (x-ald)).
For comprehensive analysis of Certara’s filings and grants, buy the databook here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.